Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

24.6%

14 terminated/withdrawn out of 57 trials

Success Rate

72.5%

-14.0% vs industry average

Late-Stage Pipeline

21%

12 trials in Phase 3/4

Results Transparency

114%

42 of 37 completed trials have results

Key Signals

5 recruiting42 with results10 terminated4 withdrawn

Enrollment Performance

Analytics

Phase 2

26(48.1%)

Phase 1

12(22.2%)

Phase 3

10(18.5%)

N/A

4(7.4%)

Phase 4

2(3.7%)

54Total

Phase 2(26)

Phase 1(12)

Phase 3(10)

N/A(4)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (57)

Showing 20 of 57 trials

NCT07519902Phase 3Recruiting

An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED

Role: lead

NCT07453888Phase 3Recruiting

Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Role: lead

NCT07503886Phase 2Recruiting

An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease

Role: lead

NCT05496868Phase 2Completed

Add-on Reparixin in Adult Patients With ARDS

Role: lead

NCT05835466Phase 2Recruiting

Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)

Role: collaborator

NCT07395232Phase 3Recruiting

An Efficacy and Safety Study of DFL24498 in the Treatment of AKC

Role: lead

NCT05254990Phase 3Terminated

Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

Role: lead

NCT06244316Phase 2Completed

A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.

Role: lead

NCT05758753Not ApplicableSuspended

QST for Corneal Nerve Function

Role: collaborator

NCT04628481Phase 2Terminated

A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function

Role: lead

NCT05552261Completed

DEFENDO Long Term Follow-up Study in Stage 1 NK Patients

Role: lead

NCT05136170Phase 3Completed

Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease

Role: lead

NCT06411132Terminated

Study to Evaluate Corneal Neurosensory Abnormalities in Patients With Sjögren's Dry Eye

Role: lead

NCT04485546Phase 4Completed

Study to Evaluate OXERVATE® in Patients With Stage 1 Neurotrophic Keratitis

Role: lead

NCT04899271Phase 2Terminated

A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.

Role: lead

NCT04627571Completed

Corneal Nerves After Treatment With Cenegermin

Role: collaborator

NCT02510235Not ApplicableCompleted

Tolerability, Safety and Efficacy of Lubricin vs Sodium Hyaluronate Eye Drops in Subjects With Moderate Dry Eye

Role: lead

NCT05368402Phase 2Terminated

Clinical Trial on Ladarixin Adjunctive Therapy to Improve Glycemic Control in Type 1 Diabetes.

Role: lead

NCT03031470Phase 2Terminated

Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver Transplantation

Role: lead

NCT04802967Phase 1Completed

A Study on Ketoprofen Lysine Salt (KLS) + Gabapentin (GABA) vs KLS to Investigate Their Pharmacodynamic in Healthy Males

Role: lead